EP 3897652 A1 20211027 - SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS
Title (en)
SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS
Title (de)
SUBSTITUIERTE PYRAZOLOPYRIMIDINE UND SUBSTITUIERTE PURINE UND IHRE VERWENDUNG ALS INHIBITOREN DER UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1)
Title (fr)
PYRAZOLOPYRIMIDINES SUBSTITUÉES ET PURINES SUBSTITUÉES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PROTÉASE 1 DE TRAITEMENT SPÉCIFIQUE DE L'UBIQUITINE
Publication
Application
Priority
- US 201862783014 P 20181220
- US 201962799423 P 20190131
- US 201962857986 P 20190606
- US 201962868616 P 20190628
- US 201962946263 P 20191210
- US 2019067521 W 20191219
Abstract (en)
[origin: WO2020132269A1] The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5', R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.
IPC 8 full level
A61K 31/519 (2006.01); A61P 35/00 (2006.01); C07D 487/04 (2006.01)
CPC (source: EP IL KR US)
A61K 31/519 (2013.01 - IL KR); A61P 35/00 (2018.01 - EP IL KR US); C07D 473/00 (2013.01 - EP); C07D 487/04 (2013.01 - EP IL KR US); C12Q 1/6886 (2013.01 - IL KR US); C12Q 2600/156 (2013.01 - IL KR US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020132269 A1 20200625; AU 2019405925 A1 20210729; BR 112021010715 A2 20211116; CA 3122108 A1 20200625; CL 2021001575 A1 20220603; CN 113164485 A 20210723; CO 2021009078 A2 20211029; EP 3897652 A1 20211027; EP 3897652 A4 20220914; IL 284050 A 20210831; JP 2022511515 A 20220131; KR 20210105887 A 20210827; MX 2021007179 A 20210928; SG 11202106232T A 20210729; TW 202039501 A 20201101; TW I834784 B 20240311; US 11485736 B2 20221101; US 11787813 B2 20231017; US 2021115049 A1 20210422; US 2023203046 A1 20230629
DOCDB simple family (application)
US 2019067521 W 20191219; AU 2019405925 A 20191219; BR 112021010715 A 20191219; CA 3122108 A 20191219; CL 2021001575 A 20210616; CN 201980079551 A 20191219; CO 2021009078 A 20210712; EP 19897934 A 20191219; IL 28405021 A 20210615; JP 2021531985 A 20191219; KR 20217017482 A 20191219; MX 2021007179 A 20191219; SG 11202106232T A 20191219; TW 108146728 A 20191219; US 201916721079 A 20191219; US 202218045770 A 20221011